|
|
肾癌治疗的研究进展
|
Abstract:
肾细胞癌是泌尿系统中常见的肿瘤类型之一，且患病人数逐年增加，严重危害着人类的健康。随着世界医疗水平的不断发展和提高，肾细胞癌的治疗方法不断得到改善。本文就近年来关于肾癌治疗的最新进展进行相关综述和探讨。
Renal cell carcinoma is one of the common types of tumors in the urinary system, and the number of patients is increasing year by year, seriously endangering human health. With the continuous development and improvement of the world’s medical level, the treatment of renal cell carcinoma has been continuously improved. This article reviews and discusses the latest advances in the treatment of kidney cancer in recent years.
| [1] | Rini, B.I., Campbell, S.C. and Escudier, B. (2009) Renal Cell Carcinoma. The Lancet, 373, 1119-1132. https://doi.org/10.1016/s0140-6736(09)60229-4 |
| [2] | Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. https://doi.org/10.3322/caac.21442 |
| [3] | Jani, C., Abdallah, N., Mouchati, C., Jani, R., Sharma, R., Bhatt, P., et al. (2022) Trends of Kidney Cancer Burden from 1990 to 2019 in European Union 15+ Countries and World Health Organization Regions. Scientific Reports, 12, Article No. 22368. https://doi.org/10.1038/s41598-022-25485-8 |
| [4] | Xu, W., Liu, W., Xu, Y., Tian, X., Anwaier, A., Su, J., et al. (2021) Hexokinase 3 Dysfunction Promotes Tumorigenesis and Immune Escape by Upregulating Monocyte/Macrophage Infiltration into the Clear Cell Renal Cell Carcinoma Microenvironment. International Journal of Biological Sciences, 17, 2205-2222. https://doi.org/10.7150/ijbs.58295 |
| [5] | Kimelberg, H.K. (1975) Alterations in Phospholipid-Dependent (Na++K+)-ATPase Activity Due to Lipid Fluidity. Effects of Cholesterol and Mg2+. Biochimica et Biophysica Acta (BBA)—Biomembranes, 413, 143-156. https://doi.org/10.1016/0005-2736(75)90065-6 |
| [6] | Tjahjono, R., Phung, D., Gurney, H., Gupta, R., Riffat, F. and Palme, C.E. (2020) Thyroid Gland Metastasis from Renal Cell Carcinoma: A Case Series and Literature Review. ANZ Journal of Surgery, 91, 708-715. https://doi.org/10.1111/ans.16482 |
| [7] | Atkins, M.B. and Tannir, N.M. (2018) Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Cancer Treatment Reviews, 70, 127-137. https://doi.org/10.1016/j.ctrv.2018.07.009 |
| [8] | Ravi, P., Bakouny, Z., Schmidt, A. and Choueiri, T.K. (2020) Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. The Cancer Journal, 26, 464-470. https://doi.org/10.1097/ppo.0000000000000477 |
| [9] | Robson, C.J., Churchill, B.M. and Anderson, W. (1969) The Results of Radical Nephrectomy for Renal Cell Carcinoma. Journal of Urology, 101, 297-301. https://doi.org/10.1016/s0022-5347(17)62331-0 |
| [10] | Ljungberg, B., Cowan, N.C., Hanbury, D.C., Hora, M., Kuczyk, M.A., Merseburger, A.S., et al. (2010) EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. European Urology, 58, 398-406. https://doi.org/10.1016/j.eururo.2010.06.032 |
| [11] | Campbell, S.C., Novick, A.C., Belldegrun, A., Blute, M.L., Chow, G.K., Derweesh, I.H., et al. (2009) Guideline for Management of the Clinical T1 Renal Mass. Journal of Urology, 182, 1271-1279. https://doi.org/10.1016/j.juro.2009.07.004 |
| [12] | Ghandour, R.A., Danzig, M.R. and McKiernan, J.M. (2015) Renal Cell Carcinoma: Risks and Benefits of Nephron-Sparing Surgery for T1 Tumors. Advances in Chronic Kidney Disease, 22, 258-265. https://doi.org/10.1053/j.ackd.2015.03.006 |
| [13] | 李云天, 董洋, 陈雨昂, 等. 减瘤手术对肾癌骨转移患者预后影响: 基于SEER数据库分析[J]. 临床泌尿外科杂志, 2024, 39(5): 374-381. https://doi.org/10.13201/j.issn.1001-1420.2024.05.002 |
| [14] | 陈益楠, 杨瑞. 肾癌根治术后切口感染的易感因素调查与预防措施分析[J]. 湖北科技学院学报(医学版), 2024, 38(2): 160-164. https://doi.org/10.16751/j.cnki.2095-4646.2024.02.0160 |
| [15] | Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., et al. (2007) A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 51, 1606-1615. https://doi.org/10.1016/j.eururo.2006.11.013 |
| [16] | Choueiri, T.K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M.D., Hahn, O., et al. (2018) Cabozantinib versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update. European Journal of Cancer, 94, 115-125. https://doi.org/10.1016/j.ejca.2018.02.012 |
| [17] | Motzer, R.J., Powles, T., Burotto, M., Escudier, B., Bourlon, M.T., Shah, A.Y., et al. (2022) Nivolumab plus Cabozantinib versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma (Checkmate 9ER): Long-Term Follow-Up Results from an Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 23, 888-898. https://doi.org/10.1016/s1470-2045(22)00290-x |
| [18] | Kim, W.Y. and Kaelin, W.G. (2004) Role of VHL Gene Mutation in Human Cancer. Journal of Clinical Oncology, 22, 4991-5004. https://doi.org/10.1200/jco.2004.05.061 |
| [19] | Choueiri, T.K. and Kaelin, W.G. (2020) Targeting the HIF2-VEGF Axis in Renal Cell Carcinoma. Nature Medicine, 26, 1519-1530. https://doi.org/10.1038/s41591-020-1093-z |
| [20] | Organ, S.L. and Tsao, M. (2011) An Overview of the C-Met Signaling Pathway. Therapeutic Advances in Medical Oncology, 3, S7-S19. https://doi.org/10.1177/1758834011422556 |
| [21] | Capozzi, M., De Divitiis, C., Ottaiano, A., von Arx, C., Scala, S., Tatangelo, F., et al. (2019) Lenvatinib, a Molecule with Versatile Application: From Preclinical Evidence to Future Development in Anti-Cancer Treatment. Cancer Management and Research, 11, 3847-3860. https://doi.org/10.2147/cmar.s188316 |
| [22] | Choueiri, T.K., Eto, M., Motzer, R., De Giorgi, U., Buchler, T., Basappa, N.S., et al. (2023) Lenvatinib plus Pembrolizumab versus Sunitinib as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (CLEAR): Extended Follow-Up from the Phase 3, Randomised, Open-Label Study. The Lancet Oncology, 24, 228-238. https://doi.org/10.1016/s1470-2045(23)00049-9 |
| [23] | Motzer, R.J., Hutson, T.E., Glen, H., Michaelson, M.D., Molina, A., Eisen, T., et al. (2015) Lenvatinib, Everolimus, and the Combination in Patients with Metastatic Renal Cell Carcinoma: A Randomised, Phase 2, Open-Label, Multicentre Trial. The Lancet Oncology, 16, 1473-1482. https://doi.org/10.1016/s1470-2045(15)00290-9 |
| [24] | Albiges, L., Beckermann, K., Miller, W.H., Goh, J.C., Gajate, P., Harris, C.A., et al. (2023) Belzutifan plus Lenvatinib for Patients (pts) with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) after Progression on a PD-1/L1 and VEGF Inhibitor: Preliminary Results of Arm B5 of the Phase 1/2 KEYMAKER-U03B Study. Journal of Clinical Oncology, 41, 4553-4553. https://doi.org/10.1200/jco.2023.41.16_suppl.4553 |
| [25] | Motzer, R.J., Schmidinger, M., Eto, M., Suarez, C., Figlin, R., Liu, Y., et al. (2023) LITESPARK-011: Belzutifan plus Lenvatinib vs Cabozantinib in Advanced Renal Cell Carcinoma after Anti-PD-1/PD-L1 Therapy. Future Oncology, 19, 113-121. https://doi.org/10.2217/fon-2022-0802 |
| [26] | Bao, R., Qu, H., Li, B., Cheng, K., Miao, Y. and Wang, J. (2024) Knowledge Mapping of Immunotherapy for Breast Cancer: A Bibliometric Analysis from 2013 to 2022: A Correspondence. Human Vaccines & Immunotherapeutics, 20, Article ID: 2352278. https://doi.org/10.1080/21645515.2024.2352278 |
| [27] | 唐晓义, 刘婷, 张斌, 等. 树突状细胞免疫治疗转移性肾细胞癌临床转化的现状[J]. 中国肿瘤生物治疗杂志, 2013, 20(5): 609-617. |
| [28] | 何立香. DC-CIK联合化疗治疗晚期NSCLC的临床研究[D]: [硕士学位论文]. 长沙: 中南大学, 2014. |
| [29] | 惠丽娜, 范开席, 徐忠法. 肾细胞癌的治疗方法及应用现状[J]. 山东医药, 2015, 55(14): 102-103. |
| [30] | 张澎, 张静, 刘亮, 等. CIK治疗转移性肾癌的临床疗效评价及预后影响因素分析[J]. 中国肿瘤临床, 2012, 39(10): 732-735. |
| [31] | Yamamoto, S., Nakayama, T., Seki, H., Kawada, C., Fukuhara, H., Karashima, T., et al. (2021) Sunitinib with Photoirradiation-Mediated Reactive Oxygen Species Generation Induces Apoptosis of Renal Cell Carcinoma Cells. Photodiagnosis and Photodynamic Therapy, 35, Article ID: 102427. https://doi.org/10.1016/j.pdpdt.2021.102427 |
| [32] | Siva, S., Kothari, G., Muacevic, A., Louie, A.V., Slotman, B.J., Teh, B.S., et al. (2017) Radiotherapy for Renal Cell Carcinoma: Renaissance of an Overlooked Approach. Nature Reviews Urology, 14, 549-563. https://doi.org/10.1038/nrurol.2017.87 |
| [33] | Tunio, M.A., Hashmi, A. and Rafi, M. (2010) Need for a New Trial to Evaluate Postoperative Radiotherapy in Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Annals of Oncology, 21, 1839-1845. https://doi.org/10.1093/annonc/mdq028 |
| [34] | Lim, S.H., Hwang, I.G., Ji, J.H., Oh, S.Y., Yi, J.H., Lim, D.H., et al. (2016) Intrinsic Resistance to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Asia-Pacific Journal of Clinical Oncology, 13, 61-67. https://doi.org/10.1111/ajco.12465 |
| [35] | Li, S., Yang, J., Wang, J., Gao, W., Ding, Y., Ding, Y., et al. (2018) Down-Regulation of miR-210-3p Encourages Chemotherapy Resistance of Renal Cell Carcinoma via Modulating ABCC1. Cell & Bioscience, 8, Article No. 9. https://doi.org/10.1186/s13578-018-0209-3 |
| [36] | van der Mijn, J.C., Mier, J.W., Broxterman, H.J. and Verheul, H.M. (2014) Predictive Biomarkers in Renal Cell Cancer: Insights in Drug Resistance Mechanisms. Drug Resistance Updates, 17, 77-88. https://doi.org/10.1016/j.drup.2014.10.003 |
| [37] | Long, Q., Du, Y., Liu, X., Li, X. and He, D. (2015) miR-124 Represses FZD5 to Attenuate P-Glycoprotein-Mediated Chemo-Resistance in Renal Cell Carcinoma. Tumor Biology, 36, 7017-7026. https://doi.org/10.1007/s13277-015-3369-3 |
| [38] | Wang, Z., An, H., Hou, D., Wang, M., Zeng, X., Zheng, R., et al. (2019) Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma. Advanced Materials, 31, e1807175. https://doi.org/10.1002/adma.201807175 |
